Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
85 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02273973 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | completed | Phase 2 | 334 | Genentech, Inc.INDUSTRY | 22 | May 21, 2018 | clinicaltrials |
| NCT00950300 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | completed | Phase 3 | 596 | Hoffmann-La RocheINDUSTRY | 26 | Jan 23, 2018 |
| clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT00099177 | A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain | terminated | Phase 3 | 96 | Hoffmann-La RocheINDUSTRY | 16 | Aug 16, 2017 | clinicaltrials |
| NCT00099203 | A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease | terminated | Phase 3 | 163 | Hoffmann-La RocheINDUSTRY | 18 | Aug 16, 2017 | clinicaltrials |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | terminated | Phase 2 / Phase 3 | 415 | Hoffmann-La RocheINDUSTRY | 28 | May 12, 2017 | clinicaltrials |
| NCT02721641 | A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer | completed | Phase 3 | 69 | Hoffmann-La RocheINDUSTRY | 17 | Mar 31, 2017 | clinicaltrials |
| NCT00196924 | Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. | completed | Phase 3 | 2,067 | GlaxoSmithKlineINDUSTRY | 12 | Mar 23, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT01450696 | A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer(HELOISE) | terminated | Phase 3 | 296 | Hoffmann-La RocheINDUSTRY | 25 | Nov 28, 2016 | clinicaltrials |
| NCT02748213 | A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | completed | Phase 2 | 225 | Hoffmann-La RocheINDUSTRY | 15 | Nov 22, 2016 | clinicaltrials |
| NCT01662869 | A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | completed | Phase 3 | 564 | Hoffmann-La RocheINDUSTRY | 24 | Nov 2, 2016 | clinicaltrials |
| NCT02563054 | A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer | completed | Phase 3 | 316 | Hoffmann-La RocheINDUSTRY | 14 | Nov 2, 2016 | clinicaltrials |
| NCT00069095 | A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,035 | Hoffmann-La RocheINDUSTRY | 33 | Oct 6, 2016 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT02559583 | Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America(HOLA) | completed | — | 5,443 | Janssen-Cilag Ltd.INDUSTRY | 7 | Jul 20, 2016 | clinicaltrials |
| NCT00602745 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen(S-1 Pancreas) | terminated | Phase 3 | 61 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT01875393 | Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer(PCM304) | completed | Phase 3 | 81 | Steba Biotech S.A.OTHER | 3 | Apr 19, 2016 | clinicaltrials |
| NCT00333775 | A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer | completed | Phase 3 | 736 | Hoffmann-La RocheINDUSTRY | 24 | Jan 27, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
| NCT01969396 | Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology | terminated | N/A | 2 | Cook Group IncorporatedINDUSTRY | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01041404 | ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer | completed | Phase 3 | 584 | Hoffmann-La RocheINDUSTRY | 24 | Nov 5, 2014 | clinicaltrials |
| NCT00720798 | An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies | completed | Phase 3 | 2,067 | Hoffmann-La RocheINDUSTRY | 34 | Sep 30, 2014 | clinicaltrials |
| NCT00475670 | A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer | completed | Phase 2 | 44 | Hoffmann-La RocheINDUSTRY | 15 | Sep 15, 2014 | clinicaltrials |
| NCT00262067 | A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) | unknown | Phase 3 | 1,237 | Genentech, Inc.INDUSTRY | 22 | Dec 13, 2013 | clinicaltrials |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | completed | Phase 3 | 760 | GlaxoSmithKlineINDUSTRY | 34 | Aug 21, 2013 | clinicaltrials |
| NCT00864331 | Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy | completed | Phase 3 | 251 | International Atomic Energy AgencyOTHER_GOV | 13 | Aug 7, 2013 | clinicaltrials |
| NCT01168791 | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma(PICASSO III) | completed | Phase 3 | 447 | Alaunos TherapeuticsINDUSTRY | 21 | Jul 18, 2013 | clinicaltrials |
| NCT00316706 | Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine | completed | Phase 3 | 1,245 | GlaxoSmithKlineINDUSTRY | 5 | Sep 18, 2012 | clinicaltrials |
| NCT00393939 | Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer(SUN 1064) | completed | Phase 3 | 594 | PfizerINDUSTRY | 27 | Jul 19, 2012 | clinicaltrials |
| NCT01033981 | Cost Effectiveness Of Sunitinib In Central America And Caribbean | terminated | — | 4 | PfizerINDUSTRY | 1 | Apr 19, 2012 | clinicaltrials |
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | approved for marketing | — | — | PfizerINDUSTRY | 50 | Mar 9, 2012 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials